CJC-1295 No DAC + Ipamorelin: Identity, Hormone Claims and Blend Evidence
This entry has two separate questions to resolve: which molecule the No DAC label identifies, and what happens when that verified material is combined with ipamorelin. Answering only one is insufficient to validate the finished blend.
FDA’s 2024 scientific briefing treats CJC-1295 and its DAC form as different active moieties. The long-acting form’s human findings should therefore remain attached to that material. FDA scientific assessment.
This selected appraisal did not establish an original outcome trial matching the exact No DAC and ipamorelin formulation. It explains the evidence needed to move from an ingredient rationale to a defensible blend claim.
Two gates before a benefit claim
Identity match
Specify exactly what No DAC means in this material.
Combination test
Compare the finished pair with relevant controls.
Benefit assessment
Measure the outcome readers actually care about.
A clear ingredient list is necessary but not sufficient. It does not show how the ingredients interact, whether the ratio is useful or whether the finished preparation remains stable.
Why the No DAC label needs documentation
A research match should include sequence, terminal groups, modifications and preparation. If these are absent, a familiar label cannot replace them. Do not select a long-acting study merely because its title contains CJC-1295.
The No DAC component profile explains the identity problem. The DAC profile covers related long-acting research. Keeping those records separate prevents a borrowed duration claim from becoming an apparent fact about this blend.
This appraisal does not assign an exact No DAC half-life to a material whose identity has not been established. Nor does it infer that removing a modification automatically produces a particular clinical timetable.
What ipamorelin’s human pharmacology contributes
A human volunteer study characterized ipamorelin exposure and GH release after intravenous administration. It did not test this No DAC blend. Original ipamorelin study.
That work can inform the component’s research background. It cannot determine the combined response or validate a different route and formulation. The ipamorelin profile provides the ingredient-level context.
When reading a claim about the pair, inspect the methods for both ingredients. If only one was administered, the paper belongs in the component-evidence column. That classification is more useful than counting how many citations appear below the claim.
What related combination research can and cannot show
An older human experiment examined GHRH(1-29) with GHRP-2 and did not demonstrate synergy under its tested conditions. Those were different materials from this listing. Original related experiment.
The study illustrates why an interaction must be measured. It is neither proof that this pair works nor proof that it cannot work. Related signaling can suggest a research question without predicting the outcome of a different combination.
A useful evidence table should identify the exact pair, population, endpoint and comparison. Leaving the molecule column vague makes even an accurately quoted result difficult to interpret.
The difference between a pulse and a benefit
A hormone response is an intermediate measurement. A claim about improved strength, sleep, recovery or fat loss needs evidence for that specific outcome. One should not be substituted for the other.
| Popular claim | Necessary evidence question |
|---|---|
| Larger GH pulses | Was the exact blend measured over time? |
| Better recovery | Was recovery defined and compared? |
| More lean mass | Was body composition assessed appropriately? |
| Improved sleep | Were sleep outcomes actually measured? |
| Safer stimulation | Were harms assessed against a relevant comparator? |
The table is an appraisal tool, not a list of established benefits. For a fuller explanation, see hormone levels versus benefits.
What a convincing blend study would include
First, characterize both ingredients and their proportions. Then compare the finished preparation with appropriate controls and the ingredients separately. That would help identify whether the second ingredient adds anything beyond the first.
If the claim is synergy, specify how the expected combined effect is calculated. A result larger than either ingredient alone may still leave that statistical question unresolved. A study should also report uncertainty rather than presenting only a best-case response.
The clinical endpoint should match the proposed use. A favorable hormone curve cannot settle a recovery claim when recovery was not measured. Safety monitoring and follow-up should accompany the benefit assessment rather than being inferred from a lack of obvious short-term problems.
Fixed ratios and separate schedules
A ratio printed on a label documents a formulation choice. It does not establish that the proportion is optimal. To support that claim, look for direct comparisons of relevant formulations on both desired and unwanted outcomes.
The same applies to timing. Combining two schedules copied from separate sources does not create a tested combination protocol. This profile does not provide an administration or dose-escalation plan from the limited evidence reviewed.
If a paper reports a particular route, preserve that context. A result should not move between infusion, injection or another delivery method without a justified exposure comparison.
Quality and clinical evidence answer different questions
A material can have analytical documentation while its clinical value remains unresolved. Identity testing, impurity assessment and preparation quality are important, but none by itself demonstrates that the blend improves a meaningful outcome.
For a premixed preparation, ask whether the analytical evidence concerns the finished mixture or only the separate starting ingredients. A component certificate is not automatically a finished-product stability study. See reading a purity claim and blend evidence.
Frequently asked questions
Does the DAC study establish this blend’s duration?
No. It concerns a different specified material and does not test the pair.
Are two plausible mechanisms enough to prove synergy?
No. A direct comparison and a defined interaction analysis are needed.
Does ipamorelin research eliminate the identity gap?
No. Identifying one ingredient does not identify the other or test the finished formulation.
What is a reasonable expected result?
This appraisal cannot provide a reliable magnitude, onset or duration of benefit for the exact listing.
Sources and editorial scope
The FDA briefing supports the dated scientific identity distinction. Original ipamorelin and related GHRH/GHRP-2 abstracts supply background only. This selected search did not establish a matched primary trial of the exact blend.